Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). 5-aminolaevulinic acid (Ameluz®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1074. 2013 Authors' conclusions 5-aminolaevulinic acid (Ameluz®) is recommended as an option for restricted use within NHS Wales for the treatment of actinic keratosis of mild to moderate intensity on the face and scalp (Olsen grade 1 to 2) when photodynamic therapy is considered appropriate. Indexing Status Subject indexing assigned by CRD MeSH Aminolevulinic Acids; Keratosis, Actinic Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32013001024 Date abstract record published 19/12/2013 |
